HMGB1 promotes HCC resistance to sorafenib by stimulating the downstream MAPK cascade through Erk1/2 phosphorylation, activating autophagy, and eventually inhibiting cancer cell apoptosis [30]. The gene discussed is MAPK3; the disease is cancer.